JW Pharmaceutical

Dyslipidemia franchise of Livalo and its combinations (Livalo V, Livalo Z, the triple combination Livalo HI); the quadruple combination Livalozet HI is in phase 3.

Third-generation three-chamber parenteral nutrition product based on fish oil; WINUF A+, an amino acid and lipid formulation, was added in 2023.

Once-every-two-weeks subcutaneous GLP-1 receptor agonist in-licensed from China's Gan & Lee Pharmaceuticals in April 2026 with exclusive Korean development and commercialization rights, developed for obesity and type 2 diabetes.

Type 2 diabetes fixed-dose combination of anagliptin (Gardlet) and empagliflozin; in a 24-week phase 3 at 26 Korean hospitals it lowered HbA1c by 0.81 percentage points.

Production complex in Dangjin, South Chungcheong Province, that the company describes as Korea's largest integrated pharmaceutical manufacturing facility.

Presented EMPA-GUARD phase 3 results at EASD 2026: in patients inadequately controlled on metformin and empagliflozin, 55.7% reached HbA1c of 7.0% or below versus 25.5% in the control group.

Acquired 100% of Solidus Investment, a biotech and healthcare venture capital firm, for 30.7 billion won to link early-stage biotech scouting and investment with co-development and technology licensing.

Filed Korean phase 3 trial applications for bofanglutide with the Ministry of Food and Drug Safety: one in 300 adults with obesity or overweight (August 18) and one in 174 type 2 diabetes patients on metformin plus an SGLT-2 inhibitor (August 28).

Secured exclusive Korean development and commercialization rights to bofanglutide, a once-every-two-weeks GLP-1 receptor agonist, from China's Gan & Lee Pharmaceuticals.